These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36877058)

  • 1. Molecular Mechanisms of Resistance to Ceftazidime/Avibactam in Clinical Isolates of
    Mojica MF; De La Cadena E; García-Betancur JC; Porras J; Novoa-Caicedo I; Páez-Zamora L; Pallares C; Appel TM; Radice MA; Castañeda-Méndez P; Gales AC; Munita JM; Villegas MV
    mSphere; 2023 Apr; 8(2):e0065122. PubMed ID: 36877058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of ceftazidime/avibactam and comparators against carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates collected globally between 2016 and 2018.
    Kiratisin P; Kazmierczak K; Stone GG
    J Glob Antimicrob Resist; 2021 Dec; 27():132-141. PubMed ID: 34478880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of clinically isolated
    Li H; Oliver A; Shields RK; Kamat S; Stone G; Estabrook M
    Antimicrob Agents Chemother; 2024 Oct; 68(10):e0067024. PubMed ID: 39254297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of ceftazidime-avibactam against Enterobacterales and Pseudomonas aeruginosa isolates collected in Latin America as part of the ATLAS global surveillance program, 2017-2019.
    Karlowsky JA; Kazmierczak KM; Valente MLNF; Luengas EL; Baudrit M; Quintana A; Irani P; Stone GG; Sahm DF
    Braz J Infect Dis; 2021; 25(6):101647. PubMed ID: 34774471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of
    Wang L; Zhang X; Zhou X; Yang F; Guo Q; Wang M
    Microbiol Spectr; 2023 Jun; 11(3):e0093223. PubMed ID: 37199669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
    Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
    Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical
    Babouee Flury B; Bösch A; Gisler V; Egli A; Seiffert SN; Nolte O; Findlay J
    Front Cell Infect Microbiol; 2023; 13():1098944. PubMed ID: 37180441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing
    Soto KD; Alcalde-Rico M; Ugalde JA; Olivares-Pacheco J; Quiroz V; Brito B; Rivas LM; Munita JM; García PC; Wozniak A
    Front Cell Infect Microbiol; 2024; 14():1410834. PubMed ID: 38903939
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of activity of ceftazidime-avibactam due to MexAB-OprM efflux and overproduction of AmpC cephalosporinase in Pseudomonas aeruginosa isolated from patients suffering from cystic fibrosis.
    Chalhoub H; Sáenz Y; Nichols WW; Tulkens PM; Van Bambeke F
    Int J Antimicrob Agents; 2018 Nov; 52(5):697-701. PubMed ID: 30081137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial susceptibility study and molecular epidemiology of ceftazidime/avibactam against
    Hu Y; Chen J; Huang L; Liu C; Zhou H; Zhang R
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36753319
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessment of the
    Viala B; Zaidi FZ; Bastide M; Dumont Y; Le Moing V; Jean-Pierre H; Godreuil S
    Microb Drug Resist; 2019 Nov; 25(9):1325-1329. PubMed ID: 31225764
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidemiology and in vitro activity of ceftazidime-avibactam and comparator agents against multidrug-resistant isolates of Enterobacterales and Pseudomonas aeruginosa collected in Latin America as part of the ATLAS surveillance program in 2015‒2020.
    Wise MG; Karlowsky JA; Lemos-Luengas EV; Valdez RR; Sahm DF
    Braz J Infect Dis; 2023; 27(3):102759. PubMed ID: 36977498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres.
    Hirsch EB; Brigman HV; Zucchi PC; Chen A; Anderson JC; Eliopoulos GM; Cheung N; Gilbertsen A; Hunter RC; Emery CL; Bias TE
    J Glob Antimicrob Resist; 2020 Sep; 22():689-694. PubMed ID: 32353524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of AmpC β-Lactamase Variants and Metallo-β-Lactamases Leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam Resistance during Treatment of MDR/XDR Pseudomonas aeruginosa Infections.
    Ruedas-López A; Alonso-García I; Lasarte-Monterrubio C; Guijarro-Sánchez P; Gato E; Vázquez-Ucha JC; Vallejo JA; Fraile-Ribot PA; Fernández-Pérez B; Velasco D; Gutiérrez-Urbón JM; Oviaño M; Beceiro A; González-Bello C; Oliver A; Arca-Suárez J; Bou G
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0206721. PubMed ID: 34930034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).
    Ko WC; Stone GG
    Ann Clin Microbiol Antimicrob; 2020 Apr; 19(1):14. PubMed ID: 32238155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from sub-Saharan Africa: ATLAS Global Surveillance Program 2017-2021.
    Wise MG; Karlowsky JA; Hackel MA; Harti MA; Ntshole BME; Njagua EN; Oladele R; Samuel C; Khan S; Wadula J; Lowman W; Lembede BW; Sahm DF
    J Glob Antimicrob Resist; 2023 Dec; 35():93-100. PubMed ID: 37709139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of MexAB-OprM overexpression and mutations in efflux regulators, PBPs and chaperone proteins is responsible for ceftazidime/avibactam resistance in Pseudomonas aeruginosa clinical isolates from US hospitals.
    Castanheira M; Doyle TB; Smith CJ; Mendes RE; Sader HS
    J Antimicrob Chemother; 2019 Sep; 74(9):2588-2595. PubMed ID: 31225882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.